CSPC Pharmaceutical Group Gains NMPA Approval for SYS6040 Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
Duality Biotherapeutics Clears HKEX Hearing, Set for IPO with $2.7B Valuation
Duality Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs), has successfully...
China Biopharmaceutical Leads AI Integration with DeepSeek-R1
Since the beginning of the year, China’s self-developed AI assistant DeepSeek has made a significant...
Driving Innovation in Traditional Chinese Medicine: A Policy-Backed Renaissance
In Depth Analysis of Policy News in the Pharmaceutical Sector: A Comprehensive Guide to the...
GE Healthcare Unveils Invenia ABUS Premium for Enhanced Dense Breast Screening
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...
Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
Japan-based Daiichi Sankyo (TYO: 4568) has announced the launch of Datroway (datopotamab deruxtecan) in Japan....
Porton Pharma Solutions’ Porton Advanced Partners with Eureka Therapeutics on T-Cell Therapies
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ subsidiary Porton Advanced, a specialist...
Triastek’s 3D-Printed T20G Receives US Clinical Approval for NOAC Treatment
China-based Triastek Inc., a pharmaceutical-focused 3D printing company, has announced receiving clinical approval in the...
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the...
Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based...
Elevation Oncology Halts EO-3021 Development After Poor Phase 1 Data
US-based Elevation Oncology, Inc. (NASDAQ: ELEV) has announced the decision to terminate development of EO-3021...
Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced its subsidiary GenScipt...
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the...
Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
China-based Sino Biopharmaceutical Ltd (HKG: 1177) released its 2024 financial report, recording revenues of RMB...
Arcutis Biotherapeutics’ Zoryve Cream Nears FDA Approval for Pediatric Atopic Dermatitis
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its US partner Arcutis Biotherapeutics, Inc....
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager...
Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot...
Kintor Pharmaceutical’s KX-826 Shows Promising Results in Alopecia Phase III Trial
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced positive topline results from the long-term safety Phase...
Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the...
Hengrui’s Trastuzumab Rezetecan Nears 8th Breakthrough Therapy Designation
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its trastuzumab rezetecan (SHR-A1811), an...